| 摘要 |
The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFRl, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.
|
| 申请人 |
THE JOHNS HOPKINS UNIVERSITY;NATIONAL INSTITUTES OF HEALTH;FEINBERG, ANDREW, P.;LEVCHENKO, ANDRE;LONGO, DAN, L.;KO, MINORU, S.H. |
发明人 |
FEINBERG, ANDREW, P.;LEVCHENKO, ANDRE;LONGO, DAN, L.;KO, MINORU, S.H. |
